Literature DB >> 9129685

New sources and new antitumor drugs in development.

R B Weiss1.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9129685

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  1 in total

1.  The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study.

Authors:  James K Weick; John J Crowley; Mohamed A Hussein; Dennis F Moore; Bart Barlogie
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.